Denali Therapeutics Stock Performance
| DNLI Stock | USD 25.16 0.48 1.94% |
Denali Therapeutics has a performance score of 2 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 2.36, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Denali Therapeutics will likely underperform. Denali Therapeutics right now shows a risk of 3.45%. Please confirm Denali Therapeutics sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to decide if Denali Therapeutics will be following its price patterns.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Denali Therapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak essential indicators, Denali Therapeutics may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Actual Historical Performance (%)
One Day Return 0.73 | Five Day Return 2.22 | Year To Date Return 16.22 | Ten Year Return 15.9 | All Time Return 15.9 |
1 | Why Is Kymera Therapeutics Up 10.9 percent Since Last Earnings Report | 09/06/2024 |
2 | Disposition of 1020 shares by Sato Vicki L of Denali Therapeutics at 30.0 subject to Rule 16b-3 | 09/13/2024 |
3 | Acquisition by Ho Carole of 161160 shares of Denali Therapeutics at 20.33 subject to Rule 16b-3 | 09/25/2024 |
4 | Disposition of 40000 shares by Ryan Watts of Denali Therapeutics at 27.69 subject to Rule 16b-3 | 10/18/2024 |
5 | Analysts Estimate Arcus Biosciences, Inc. to Report a Decline in Earnings What to Look Out for | 10/30/2024 |
6 | Disposition of 3080 shares by Sato Vicki L of Denali Therapeutics at 27.07 subject to Rule 16b-3 | 11/01/2024 |
7 | Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights | 11/06/2024 |
8 | Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging | 11/08/2024 |
9 | HC Wainwright Reaffirms Buy Rating for Denali Therapeutics | 11/11/2024 |
10 | Capital Research Global Investors Expands Stake in Denali Therapeutics Inc. | 11/13/2024 |
11 | Denali Therapeutics Trading Down 8.3 percent Heres Why | 11/15/2024 |
12 | Denali Therapeutics updates bylaws, aligns with SEC rules | 11/18/2024 |
13 | Acquisition by Sato Vicki L of 17901 shares of Denali Therapeutics at 18.56 subject to Rule 16b-3 | 11/19/2024 |
14 | Disposition of 20516 shares by Schuth Alexander O. of Denali Therapeutics at 0.68 subject to Rule 16b-3 | 11/22/2024 |
| Begin Period Cash Flow | 219.5 M |
Denali |
Denali Therapeutics Relative Risk vs. Return Landscape
If you would invest 2,444 in Denali Therapeutics on August 30, 2024 and sell it today you would earn a total of 72.00 from holding Denali Therapeutics or generate 2.95% return on investment over 90 days. Denali Therapeutics is currently generating 0.1049% in daily expected returns and assumes 3.4518% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Denali, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Denali Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Denali Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Denali Therapeutics, and traders can use it to determine the average amount a Denali Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0304
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | DNLI | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.45 actual daily | 30 70% of assets are more volatile |
Expected Return
| 0.1 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Denali Therapeutics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Denali Therapeutics by adding it to a well-diversified portfolio.
Denali Therapeutics Fundamentals Growth
Denali Stock prices reflect investors' perceptions of the future prospects and financial health of Denali Therapeutics, and Denali Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Denali Stock performance.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 2.74 B | ||||
| Shares Outstanding | 143.92 M | ||||
| Price To Earning | 60.91 X | ||||
| Price To Book | 2.67 X | ||||
| Price To Sales | 3,339 X | ||||
| Revenue | 330.53 M | ||||
| Gross Profit | (250.27 M) | ||||
| EBITDA | (179.97 M) | ||||
| Net Income | (145.22 M) | ||||
| Cash And Equivalents | 1.07 B | ||||
| Cash Per Share | 8.66 X | ||||
| Total Debt | 52.24 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 3.20 X | ||||
| Book Value Per Share | 9.17 X | ||||
| Cash Flow From Operations | (357.99 M) | ||||
| Earnings Per Share | (2.76) X | ||||
| Market Capitalization | 3.55 B | ||||
| Total Asset | 1.15 B | ||||
| Retained Earnings | (1.12 B) | ||||
| Working Capital | 986.15 M | ||||
| Current Asset | 281.74 M | ||||
| Current Liabilities | 10.46 M | ||||
About Denali Therapeutics Performance
By evaluating Denali Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Denali Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Denali Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Denali Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | (298.46) | (313.38) | |
| Return On Tangible Assets | (0.13) | (0.13) | |
| Return On Capital Employed | (0.18) | (0.19) | |
| Return On Assets | (0.13) | (0.13) | |
| Return On Equity | (0.14) | (0.15) |
Things to note about Denali Therapeutics performance evaluation
Checking the ongoing alerts about Denali Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Denali Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Denali Therapeutics had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 330.53 M. Net Loss for the year was (145.22 M) with loss before overhead, payroll, taxes, and interest of (250.27 M). | |
| Denali Therapeutics currently holds about 1.07 B in cash with (357.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.66. | |
| Over 91.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from MacroaxisInsider: Disposition of 20516 shares by Schuth Alexander O. of Denali Therapeutics at 0.68 subject to Rule 16b-3 |
- Analyzing Denali Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Denali Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Denali Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Denali Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Denali Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Denali Therapeutics' stock. These opinions can provide insight into Denali Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Denali Stock analysis
When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |